Trius Therapeutics' Grant

Trius Therapeutics raised a round of funding on May 07, 2010. Investors include Defense Threat Reduction Agency.

Trius Therapeutics is discovering and developing antibacterial drugs for the treatment of life-threatening infections. The company's lead product candidate, TR-701 is a oral and IV oxazolidinone antib…

Articles about Trius Therapeutics' Grant: